Abstract
Allergic diseases, such as allergic asthma, allergic rhinitis, atopic dermatitis, conjunctivitis, urticaria, food allergy, and/or anaphylaxis, are associated with the skewing of immune responses towards a T helper 2 (TH2) phenotype, resulting in eosinophilic inflammation. TH2 cytokines, such as interleukin (IL)-4, IL-5 and IL-13, promote IgE production, mast cell differentiation, and eosinophil growth, migration and activation which then lead to the pathologic abnormalities in allergic diseases. Moreover, the impaired function of regulatory T cells has been noted in allergic diseases. To date, treatments for allergic diseases, such as antihistamines, corticosteroids, bronchodilators and some allergen-specific immunotherapy, are effective but costly and require long-term and recurrent drug administration. Gene therapy has been shown to be an easy, effective, and convenient treatment by delivering the allergen or the therapeutic protein in the form of plasmid DNA in vivo to modulate allergic immune responses. We summarize here the recent advances of gene therapy in allergic diseases and discuss the challenges in clinical application.
Keywords: Gene therapy, Allergic disease, TH2, Allergen-specific immunotherapy, Regulatory T cell, Cytokine, Viral vector
Current Gene Therapy
Title: Gene Therapy for Allergic Diseases
Volume: 9 Issue: 3
Author(s): Ya-Hui Chuang, Yao-Hsu Yang, Si-Jie Wu and Bor-Luen Chiang
Affiliation:
Keywords: Gene therapy, Allergic disease, TH2, Allergen-specific immunotherapy, Regulatory T cell, Cytokine, Viral vector
Abstract: Allergic diseases, such as allergic asthma, allergic rhinitis, atopic dermatitis, conjunctivitis, urticaria, food allergy, and/or anaphylaxis, are associated with the skewing of immune responses towards a T helper 2 (TH2) phenotype, resulting in eosinophilic inflammation. TH2 cytokines, such as interleukin (IL)-4, IL-5 and IL-13, promote IgE production, mast cell differentiation, and eosinophil growth, migration and activation which then lead to the pathologic abnormalities in allergic diseases. Moreover, the impaired function of regulatory T cells has been noted in allergic diseases. To date, treatments for allergic diseases, such as antihistamines, corticosteroids, bronchodilators and some allergen-specific immunotherapy, are effective but costly and require long-term and recurrent drug administration. Gene therapy has been shown to be an easy, effective, and convenient treatment by delivering the allergen or the therapeutic protein in the form of plasmid DNA in vivo to modulate allergic immune responses. We summarize here the recent advances of gene therapy in allergic diseases and discuss the challenges in clinical application.
Export Options
About this article
Cite this article as:
Chuang Ya-Hui, Yang Yao-Hsu, Wu Si-Jie and Chiang Bor-Luen, Gene Therapy for Allergic Diseases, Current Gene Therapy 2009; 9 (3) . https://dx.doi.org/10.2174/156652309788488604
DOI https://dx.doi.org/10.2174/156652309788488604 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Histamine H3 Receptor as a Therapeutic Drug Target for Metabolic Disorders: Status, Challenges and Opportunities
Current Topics in Medicinal Chemistry Assessment of Health-Related Quality of Life in Different Phenotypes of COPD
Current Respiratory Medicine Reviews Therapeutic Use of Chemokines
Current Pharmaceutical Design The Gut-Brain Axis, Including the Microbiome, Leaky Gut and Bacterial Translocation: Mechanisms and Pathophysiological Role in Alzheimer’s Disease
Current Pharmaceutical Design The Chemistry and Pharmacology of Tetrahydropyridines
Current Medicinal Chemistry A Practical Comprehensive Approach to Management of Acute Decompensated Heart Failure
Current Cardiology Reviews Enteric Ecosystem Disruption in Autism Spectrum Disorder: Can the Microbiota and Macrobiota be Restored?
Current Pharmaceutical Design <i>Fagonia indica</i>; A Review on Chemical Constituents, Traditional Uses and Pharmacological Activities
Current Pharmaceutical Design Causes of Secretion Retention: Patient Factors, Ventilation, Devices, Drugs
Current Respiratory Medicine Reviews Anti-Inflammatory Drugs and Herbs with Special Emphasis on Herbal Medicines for Countering Inflammatory Diseases and Disorders - A Review
Recent Patents on Inflammation & Allergy Drug Discovery Novel Pharmacologic Approaches to the Management of Sepsis: Targeting the Host Inflammatory Response
Recent Patents on Inflammation & Allergy Drug Discovery CXCR4 Receptor as a Promising Target for Oncolytic Drugs
Mini-Reviews in Medicinal Chemistry From the Deepest Sea Shelf to the Uppermost Kitchen Cabinet Shelf: The Quest for Novel TNF-α Inhibitors
Current Topics in Medicinal Chemistry Potential Applications of FDG-PET/CT in COPD: A Review of the Literature
Current Molecular Imaging (Discontinued) Chemical Composition and Antioxidant Potential of Essential Oil and Organic Extracts of Euphorbia tithymaloides L. from Kushtia Region
Anti-Cancer Agents in Medicinal Chemistry Recent Progress in the Design of Selectin Inhibitors
Mini-Reviews in Medicinal Chemistry Cyanopeptides: A New and Nearly Inexhaustible Natural Resource for the Design and Structure-Activity Relationship Studies of New Inhibitors of Trypsin-like Serine Proteases
Current Enzyme Inhibition The Pathology and Immunology of Atopic Dermatitis
Inflammation & Allergy - Drug Targets (Discontinued) Other Drugs Acting on Nervous System Associated with QT-Interval Prolongation
Current Drug Safety Cytokine-Induced Inflammatory Liver Injuries
Current Molecular Medicine